Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Innere Medizin
Erschienen in: Die Innere Medizin 6/2023

24.05.2023 | Kolorektales Karzinom | CME

Metastasiertes kolorektales Karzinom – moderne Therapiestrategien und -sequenzen

verfasst von: Dr. T. J. Ettrich, Dr. J. S. Schuhbaur, Prof. Dr. T. Seufferlein

Erschienen in: Die Innere Medizin | Ausgabe 6/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Therapie des metastasierten kolorektalen Karzinoms (mKRK) hat sich in den vergangenen Jahren durch neue Strategien wie die Resektion von Leber- und/oder Lungenmetastasen, Induktions- und Erhaltungstherapien, die Etablierung von zielgerichteten Therapien („targeted therapies“) und molekulare Therapiestrategien für definierte Subgruppen erheblich erweitert und relevant verbessert. Der vorliegende Beitrag stellt evidenzbasierte Therapieoptionen und Algorithmen mit Fokus auf die Systemtherapie dar.
Literatur
1.
Cardoso R, Zhu A, Guo F et al (2021) Incidence and mortality of proximal and distal colorectal cancer in Germany-trends in the era of screening colonoscopy. Dtsch Arztebl Int 118:281–287PubMedPubMedCentral
2.
Christensen TD, Spindler KL, Palshof JA et al (2016) Systematic review: brain metastases from colorectal cancer—incidence and patient characteristics. BMC Cancer 16:260PubMedPubMedCentralCrossRef
3.
O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American joint committee on cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425PubMedCrossRef
4.
Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835PubMedCrossRef
5.
Adam R, de Haas RJ, Wicherts DA et al (2008) Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol 26:3672–3680PubMedCrossRef
6.
Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677–3683PubMedPubMedCentralCrossRef
7.
Schoffer O, Roessler M, Bierbaum V (2022) Wirksamkeit der Versorgung in onkologischen Zentren (WiZen)
8.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2019) S3-Leitlinie Kolorektales Karzinom, Langversion 2.1 (AWMF Registrierungsnummer: 021/007OL)
9.
Boudjema K, Locher C, Sabbagh C et al (2021) Simultaneous versus delayed resection for initially resectable synchronous colorectal cancer liver metastases: a prospective, open-label, randomized, controlled trial. Ann Surg 273:49–56PubMedCrossRef
10.
Rahbari NN, Biondo S, Feißt M et al (2022) Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases. J Clin Oncol 40:LBA3507CrossRef
11.
Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318 (discussion 318–321)PubMedPubMedCentralCrossRef
12.
Hamady ZZ, Lodge JP, Welsh FK et al (2014) One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Ann Surg 259:543–548PubMedCrossRef
13.
Gotra A, Sivakumaran L, Chartrand G et al (2017) Liver segmentation: indications, techniques and future directions. Insights Imaging 8:377–392PubMedPubMedCentralCrossRef
14.
Cieslak KP, Bennink RJ, de Graaf W et al (2016) Measurement of liver function using hepatobiliary scintigraphy improves risk assessment in patients undergoing major liver resection. HPB (Oxford) 18:773–780PubMedCrossRef
15.
Shindoh J, Tzeng CW, Aloia TA et al (2013) Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 20:2493–2500PubMedCrossRef
16.
Schmiegel W, Buchberger B, Follmann M et al (2017) S3-Leitlinie – Kolorektales Karzinom. Z Gastroenterol 55:1344–1498PubMedCrossRef
17.
Boeckx N, Koukakis R, Op de Beeck K et al (2017) Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol 28:1862–1868PubMedPubMedCentralCrossRef
18.
Tejpar S, Stintzing S, Ciardiello F et al (2017) Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE‑3 trials. JAMA Oncol 3:194–201PubMedPubMedCentralCrossRef
19.
Rivera F, Karthaus M, Hecht JR et al (2017) Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis 32:1179–1190PubMedPubMedCentralCrossRef
20.
Cremolini C, Loupakis F, Antoniotti C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306–1315PubMedCrossRef
21.
Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676PubMedCrossRef
22.
Modest DP, Martens UM, Riera-Knorrenschild J et al (2019) FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109). J Clin Oncol 37:3401–3411PubMedCrossRef
23.
Bond MJG, Bolhuis K, Loosveld OJL et al (2022) LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: phase III CAIRO5 study of the Dutch colorectal cancer group. Ann Oncol 33:S1389CrossRef
24.
André T, Shiu KK, Kim TW et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383:2207–2218PubMedCrossRef
25.
Kanemitsu Y, Shimizu Y, Mizusawa J et al (2020) A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603 study. J Clin Oncol 38:4005–4005CrossRef
26.
Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26:4906–4911PubMedCrossRef
27.
Imanishi M, Yamamoto Y, Hamano Y et al (2019) Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis. Eur J Cancer 106:69–77PubMedCrossRef
28.
Douillard JY, Oliner KS, Siena S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034PubMedCrossRef
29.
De Roock W, Jonker DJ, Di Nicolantonio F et al (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812–1820PubMedCrossRef
30.
Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075PubMedCrossRef
31.
Yoshino T, Watanabe J, Shitara K et al (2022) Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial. J Clin Oncol 40:LBA1CrossRef
32.
Arnold D, Lueza B, Douillard JY et al (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28:1713–1729PubMedPubMedCentralCrossRef
33.
34.
Cremolini C, Antoniotti C, Rossini D et al (2020) Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21:497–507PubMedCrossRef
35.
Cremolini C, Rossini D, Lonardi S et al (2022) Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): results of the phase III randomized TRIPLETE study by GONO. J Clin Oncol 40:LBA3505CrossRef
36.
Cunningham D, Lang I, Marcuello E et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14:1077–1085PubMedCrossRef
37.
Seymour MT, Thompson LC, Wasan HS et al (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377:1749–1759PubMedPubMedCentralCrossRef
38.
Winther SB, Österlund P, Berglund Å et al (2017) Randomized study comparing full dose monotherapy (S‑1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S‑1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer 17:548PubMedPubMedCentralCrossRef
39.
Hegewisch-Becker S, Graeven U, Lerchenmuller CA et al (2015) Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 16(13):1355–1369. https://​doi.​org/​10.​1016/​S1470-2045(15)00042-XCrossRefPubMed
40.
41.
André T, Lonardi S, Wong KYM et al (2022) Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4‑year follow-up from CheckMate 142. Ann Oncol 33:1052–1060PubMedCrossRef
42.
Overman MJ, McDermott R, Leach JL et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18:1182–1191PubMedPubMedCentralCrossRef
43.
Antoniotti C, Rossini D, Pietrantonio F et al (2022) Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 23:876–887PubMedCrossRef
44.
Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–4713PubMedCrossRef
45.
46.
Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29–37PubMedCrossRef
47.
Tabernero J, Van Cutsem E, Lakomy R et al (2014) Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 50:320–331PubMedCrossRef
48.
Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499–508PubMedCrossRef
49.
Overman MJ, Lonardi S, Wong KYM et al (2018) Durable clinical benefit with nivolumab plus Ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36:773–779PubMedCrossRef
50.
Kopetz S, Grothey A, Cutsem EV et al (2020) Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). J Clin Oncol 38:4001–4001CrossRef
51.
Kopetz S, Grothey A, Yaeger R et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 381:1632–1643PubMedCrossRef
52.
Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312PubMedCrossRef
53.
Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909–1919PubMedCrossRef
54.
Pfeiffer P, Yilmaz M, Möller S et al (2020) TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 21:412–420PubMedCrossRef
55.
Dasari NA, Lonardi S, Garcia-Carbonero R et al (2022) LBA25 FRESCO-2: a global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. Ann Oncol 33:1391–1392CrossRef
56.
Suenaga M, Mizunuma N, Matsusaka S et al (2015) Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 9:3099–3108PubMedPubMedCentralCrossRef
57.
Siena S, Di Bartolomeo M, Raghav K et al (2021) Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 22:779–789PubMedCrossRef
58.
Yoshino T, Bartolomeo MD, Raghav KPS et al (2021) Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). J Clin Oncol 39:3505–3505CrossRef
59.
Nassar AH, Adib E, Kwiatkowski DJ (2021) Distribution of KRAS (G12C) somatic mutations across race, sex, and cancer type. N Engl J Med 384:185–187PubMedCrossRef
60.
61.
Westphalen CB, Krebs MG, Le Tourneau C et al (2021) Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol 5:69PubMedPubMedCentralCrossRef
62.
Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731–739PubMedPubMedCentralCrossRef
Metadaten
Titel
Metastasiertes kolorektales Karzinom – moderne Therapiestrategien und -sequenzen
verfasst von
Dr. T. J. Ettrich
Dr. J. S. Schuhbaur
Prof. Dr. T. Seufferlein
Publikationsdatum
24.05.2023
Verlag
Springer Medizin
Erschienen in
Die Innere Medizin / Ausgabe 6/2023
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-023-01516-y

Weitere Artikel der Ausgabe 6/2023

Die Innere Medizin 6/2023 Zur Ausgabe

Schwerpunkt: Ungewollter Gewichtsverlust in der Inneren Medizin

Sarkopenie bei chronischen Lebererkrankungen

Mitteilungen der DGIM

Mitteilungen der DGIM

Mitteilungen des BDI

MVZ im Blick

Schwerpunkt: Ungewollter Gewichtsverlust in der Inneren Medizin

Ungewollter Gewichtsverlust bei chronischer Nierenkrankheit

Kasuistiken

Ihre diagnostischen Fähigkeiten sind gefragt – junge Patientin mit akuter Pankreatitis

Einführung zum Thema

Gewichtsverlust bei chronischen Erkrankungen – eine adäquate Behandlung ist essenziell für die Betroffenen!

Weitere Lesetipps

ANZEIGE

Spagat zwischen Leitlinien und klinischem Alltag

Monitoring kardiovaskulärer Notfallpatienten: Tipps für die Notaufnahme

Empfehlungen der AGO-Kommission Mamma 2024 – was ist neu?

Aufklärungsgespräche verbessern – Herausforderungen und Lösungsansätze

ANZEIGE

Herausforderungen und Management krebsassoziierter Thrombosen

ANZEIGE

CAT: Was tun bei Lücken in der Evidenz

Bildnachweise